Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MLNR | O43193 | 7/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19002804 | 0.87 | CA1 (0.58) | CA1CA2CA4CA9ALDH1A1 | |
| SCHEMBL19049077 | 0.87 | CCR3 (0.48) | CCR3CA1CA2CA4CA9 | |
| SCHEMBL19002803 | 0.85 | CA1 (0.44) | CCR3CA1CA2CA4CA9 | |
| SCHEMBL20665204 | 0.84 | CCR3 (0.44) | CCR3CA1CA2CA4CA9 | |
| SCHEMBL21900620 | 0.84 | CCR3 (0.44) | CCR3CA1CA2CA4CA9 | |
| SCHEMBL18947215 | 0.79 | EPHX2 (0.43) | ALDH1A1SMN1; SMN2MLNRCYP3A4EPHX2 | |
| SCHEMBL13859660 | 0.76 | PLG (0.40) | CCR3ALDH1A1 | |
| SCHEMBL19002806 | 0.76 | CCR3 (0.47) | CCR3CA1CA2CA4CA9 | |
| SCHEMBL26835411 | 0.76 | CHRNB2 (0.46) | CA1CA2CA4CA9ALDH1A1 | |
| SCHEMBL16508868 | 0.74 | CHRNB2 (0.44) | CA1CA2CA4CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | CCR3 910/4885CA1 4238/4885CA2 4222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.